Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: Results from the randomised phase II part of a phase I/II study

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 933-941

  Kato, T ^a   Muro, K ^b   Yamaguchi, K ^c   Bando, H ^d   Hazama, S ^e   Amagai, K ^f   Baba, H ^g   Denda, T ^h   Shi, X ⁱ   Fukase, K ⁱ   Sakamoto, J ^j   Mishima, H ^k  

^a Minoh City Hospital   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c Saitama Cancer Centre   (Japan)

^d ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^e YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^f IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^g KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^h CHIBA CANCER CENTER   (Japan)

ⁱ ASTRAZENECA   (United Kingdom)

^j NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k OSAKA NATIONAL HOSPITAL   (Japan)

more..

Author keywords

Cediranib; Colorectal cancer; mFOLFOX6; Placebo; Progression free survival

Indexed keywords

CEDIRANIB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHONIA; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; ILEUS; JAPANESE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL TIME; VOMITING;

EID: 84859487309     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr359     Document Type: Article

References (33)

1. GLOBOCAN Database. Japan: Summary Statistics. Lyon, France: International Agency for Research on Cancer 2010; Available at: GLOBOCAN 2008
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487.
3. Japanese Society for Cancer of the Colon and Rectum. Clinical Practice Guidelines for the Treatment of Colorectal Cancer (For Physicians). Tokyo, Japan: Kanehara & Co Ltd 2005; 30-33.
4. Goldberg RM. Current approaches to first-line treatment of advanced colorectal cancer. Clin Colorectal Cancer 2004; 4: S9-S15.
5. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
6. Cunningham D, Atkin W, Lenz H-J et al. Colorectal cancer. Lancet 2010; 375: 1030-1047.
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
8. Heckman CA, Holopainen T, Wirzenius M et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 2008; 68: 4754-4762.
9. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-4400.
10. Drevs J, Siegert P, Medinger M et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 3045-3054.
11. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
12. Fiedler W, Mesters R, Heuser M et al. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk Res 2010; 34: 196-202.
13. Langenberg M, van Herpen CM, de Bono JS et al. Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: a randomized phase II study of cediranib. J Clin Oncol 2008; 26 (15S): (Abstr 3555).
14. Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27: 5601-5606.
15. Yamamoto N, Tamura T, Yamamoto N et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2009; 64: 1165-1172.
16. Laurie SA, Gauthier I, Arnold A et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced nonsmall-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008; 26: 1871-1878.
17. Chen E, Jonker D, Gauthier I et al. Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res 2009; 15: 1481-1486.
18. Goss G, Shepherd FA, Laurie S et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2009; 45: 782-788.
19. Goss GD, Arnold A, Shepherd FA et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010; 28: 49-55.
20. LoRusso P, Shields AF, Gadgeel S et al. Cediranib in combination with various anticancer regimens: results of a Phase I multi-cohort study. Invest New Drugs 2010 [epub ahead of print], doi:10.1007/s10637-010-9484-5.
21. van Cruijsen H, Voest EE, Punt CJ et al. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer 2010; 46: 901-911.
22. Hoff PM, Hocchaus A, Pestalozzi BC et al. Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): a randomized, double-blind, phase III study (HORIZON II). Ann Oncol 2010; 21 (Suppl 8): viii9. (Abstr LBA19).
23. Schmoll H-J, Cunningham D, Sobrero A et al. mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): a randomized, double-blind, phase II/III study (HORIZON III). Ann Oncol 2010; 21 (Suppl 8): viii188 (Abstr 580O).
24. Satoh T, Yamaguchi K, Boku N et al. Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. Invest New Drugs 2011 May 25 [epub ahead of print], doi:10.1007/s10637-011-9693-6.
25. Rubinstein LV, Korn EL, Freidlin B et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005; 23: 7199-7206.
26. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
27. Nagata N, Kondo K, Kato T et al. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study. Hepatogastroenterology 2009; 56: 1346-1353.
28. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008; 26: 3523-3529.
29. Doi T, Boku N, Kato K et al. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2010; 40: 913-920.
30. Akaza H, Tsukamoto T, Murai M et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-762.
31. Uemura H, Shinohara N, Yuasa T et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010; 40: 194-202.
32. Hecht JR, Trarbach T, Hainsworth JD et al. Randomized, placebo-controlled, Phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 2011; 29: 1997-2003.
33. Brave SR, Ratcliffe K, Wilson Z et al. Assessing the activity of cediranib, a VEGFR-2/-3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR-family. Mol Cancer Ther 2011; 10: 861-873.